Redhill Biopharma (Redhill Biopharma) Institutional Ownership : 0.00% (As of May. 16, 2024)

View and export this data going back to 2013. Start your Free Trial

What is Redhill Biopharma Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Redhill Biopharma's institutional ownership is 0.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Redhill Biopharma's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Redhill Biopharma's Float Percentage Of Total Shares Outstanding is 89.21%.

Redhill Biopharma Institutional Ownership Historical Data

The historical data trend for Redhill Biopharma's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Redhill Biopharma Institutional Ownership Chart

Redhill Biopharma Historical Data

The historical data trend for Redhill Biopharma can be seen below:

	2023-03-31	2023-04-30	2023-05-31	2023-06-30	2023-07-31	2023-08-31	2023-09-30	2023-10-31	2023-11-30	2023-12-31
Institutional Ownership	0.10	0.09	0.09	0.07	0.05	0.04	0.04	0.02	0.02	0.01

Redhill Biopharma Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Redhill Biopharma (Redhill Biopharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Redhill Biopharma Ltd (NAS:RDHL) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

2RH0:Germany 2RH0:Germany

Address

21 Ha’arba’a Street, Tel Aviv, ISR, 6473921

Website

https://www.redhillbio.com

Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults, Talicia for the treatment of Helicobacter pylori infection in adults, and Aemcolo for the treatment of travelers' diarrhea in adults. Its key clinical late-stage development programs include RHB-104 for Crohn's disease; RHB-204, for pulmonary nontuberculous mycobacteria infections; RHB-102 (Bekinda) with positive results from a first Phase 3 study for acute gastroenteritis and gastritis; Opaganib (Yeliva); RHB-106, an encapsulated bowel preparation and RHB-107, a Phase 2-stage serine protease inhibitor targeting cancer and inflammatory gastrointestinal diseases.